The GAO has released two reports involving prescription drugs. The first report, “Prescription Drugs: FDA’s Oversight of the Promotion of Drugs for Off-Label Uses,” found a number of shortcomings in the FDA’s review process, including FDA’s failure to prioritize its reviews in a systematic manner or consistently track the receipt and review of submitted materials. The second report, “Medicare Part D: Complaint Rates Are Declining, but Operational and Oversight Challenges Remain,” includes a number of recommendations to improve oversight of the Medicare Part D grievances process and provide added assurance that beneficiaries’ grievances are being resolved.